XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator.
Copyright policy )XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator.
CBio Ltd, under license from the University of Queensland, is developing a recombinant form of chaperonin 10, known as XToll, for the potential anti-inflammatory treatment of rheumatoid arthritis, psoriasis and multiple sclerosis. All three indications have been evaluated in phase IIa clinical trials. By May 2005, a phase IIa trial for Crohn's disease had been terminated due to slow recruitment. The company has not disclosed plans for future development for this indication.
- Utrecht University Netherlands
- Amsterdam institute for Immunology and Infectious Diseases Netherlands
- University Museum Utrecht Netherlands
Clinical Trials as Topic, Multiple Sclerosis, Anti-Inflammatory Agents, Drug Evaluation, Preclinical, Recombinant Proteins, Autoimmune Diseases, Arthritis, Rheumatoid, Structure-Activity Relationship, Chaperonin 10, Animals, Humans, Immunologic Factors, Psoriasis
Clinical Trials as Topic, Multiple Sclerosis, Anti-Inflammatory Agents, Drug Evaluation, Preclinical, Recombinant Proteins, Autoimmune Diseases, Arthritis, Rheumatoid, Structure-Activity Relationship, Chaperonin 10, Animals, Humans, Immunologic Factors, Psoriasis
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).7 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!